1. Record Nr. UNINA9910144409203321

| | |
|---|---|
| Autore | Turner J. Rick |
| Titolo | Integrated cardiac safety [[electronic resource] ] : assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance / / J. Rick Turner, Todd A. Durham |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| ISBN | 1-282-00206-6<br>9786612002069<br>0-470-41129-5<br>0-470-41128-7 |
| Edizione | [1st ed.] |
| Descrizione fisica | 1 online resource (500 p.) |
| Altri autori (Persone) | DurhamTodd A |
| Disciplina | 616.1/23061 |
| Soggetti | Cardiovascular toxicology<br>Heart - Effect of drugs on<br>Drugs - Side effects - Testing<br>Drugs - Safety measures |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Description based upon print version of record. |
| Nota di bibliografia | Includes bibliographical references (p. 397-455) and index. |
| Nota di contenuto | The importance of cardiac safety assessments -- The biological basis of adverse drug reactions -- Cardiac structure and function -- Cardiac pathophysiology and disease -- Drug discovery and drug design -- Nonclinical development -- The thorough QT/QTc trial -- General safety assessments -- Therapeutic use trials and meta-analyses -- Assessment methodologies in nonexperimental postmarketing surveillance -- Postmarketing proarrhythmic cardiac safety assessments -- Generalized cardiac safety -- Medication errors, adherence, and concordance -- Future directions in drug safety. |
| Sommario/riassunto | The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug's life, from discovery and development through postmarketing research. This self-contained, |

reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, g